# A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

> **NCT01717300** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 459 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Anacetrapib 100 mg
- **DRUG:** Placebo for anacetrapib 100 mg
- **DRUG:** Anacetrapib 25 mg
- **DRUG:** Placebo for anacetrapib 25 mg

## Key facts

- **NCT ID:** NCT01717300
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-06
- **Primary completion:** 2014-10-29
- **Final completion:** 2014-10-29
- **Target enrollment:** 459 (ACTUAL)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01717300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01717300, "A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01717300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*